Silence Therapeutics plc filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter ended September 30, 2026, and disclosing a significant increase in cash and cash equivalents alongside a pending acquisition by Merck KGaA, Darmstadt, Germany.
Key Highlights
- Cash position: Cash and cash equivalents stood at $247,659 thousand as of September 30, 2026, compared to $11,277 thousand as of December 31, 2025.
- Short-term investments: Short-term investments were zero as of September 30, 2026, down from $73,837 thousand at December 31, 2025.
- Total assets: Total assets were $281,498 thousand as of September 30, 2026, versus $131,442 thousand at December 31, 2025.
- Shares outstanding: As of September 30, 2026, the registrant had 186,609,073 ordinary shares outstanding, nominal value £0.05 per share.
- Pending acquisition: The filing identifies a proposed acquisition by Merck KGaA, Darmstadt, Germany, among its forward-looking disclosures, noting uncertainty around structure, timing, and ability to consummate the transaction.
- Liquidity outlook: The company disclosed a belief that "existing cash, cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements at least until 2028."
- Filer classification: Silence Therapeutics is classified as a non-accelerated filer and a smaller reporting company for this period.
Silence Therapeutics Reports Sharp Rise in Cash and Total Assets for September 30, 2026 Quarter
Silence Therapeutics plc (NASDAQ:SLN), a company incorporated in England and Wales and headquartered at 12 Hammersmith Grove, London, United Kingdom, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, cash and cash equivalents increased sharply to $247,659 thousand at September 30, 2026, from $11,277 thousand at December 31, 2025. Over the same period, short-term investments fell from $73,837 thousand to zero, and total current assets rose from $118,658 thousand to $269,576 thousand.
The filing reports total assets of $281,498 thousand at September 30, 2026, up from $131,442 thousand at December 31, 2025. Other balance sheet items disclosed include goodwill of $10,254 thousand (compared to $10,621 thousand at year-end 2025), property, plant and equipment of $1,222 thousand, and an R&D benefit receivable of $9,973 thousand, down from $22,007 thousand at December 31, 2025. Total current liabilities were $(11,259) thousand at September 30, 2026, compared to $(13,613) thousand at December 31, 2025, with trade and other payables of $(11,172) thousand.
The filing discloses a proposed acquisition by Merck KGaA, Darmstadt, Germany, as a subject of forward-looking statements, with the company noting risks around the structure, timing, and ability to complete the transaction. The company's forward-looking statements are, according to the filing, subject to known and unknown risks and uncertainties, and "you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report." The filing was submitted with Commission File Number 001-39487.
What Was Disclosed
Silence Therapeutics plc filed its Form 10-Q for the quarter ended September 30, 2026, reporting a large increase in cash and total assets versus year-end 2025, 186,609,073 ordinary shares outstanding, and a pending proposed acquisition by Merck KGaA, Darmstadt, Germany.




Please wait processing your request...